Compounds having the formula
1
are hepatitis C (HCV) polymerase inhibitors. Also disclosed are a composition and method for inhibiting hepatitis C (HCV) polymerase, processes for making the compounds, and synthetic intermediates employed in the processes.
The invention is directed to pyridazinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.
Compounds useful as HCV anti-infectives having the formula (I) wherein the formula variables are as defined herein, are disclosed. Also disclosed are methods of making and using the same.